Cited 1 times in
Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.